Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cara Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Cara Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	2.2%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$2.03
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Jul 18

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

May 29

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

May 25

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Feb 16

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Dec 19

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

Nov 04

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Oct 25

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Jul 20

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Jun 04

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Mar 11

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Feb 15

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Feb 06

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Oct 18

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Sep 28

Cara Therapeutics hires new finance chief

Sep 12

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Sep 01

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Aug 19

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Aug 08

Calls A Much Safer Way To Buy Cara Therapeutics

Jun 24

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Jun 15

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

May 12

Taking A (Speculative) Position In Cara Therapeutics

Mar 21

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Mar 09

Cara Therapeutics: De-Risked And Extremely Attractive

Dec 25

Checking Back In On Cara Therapeutics

Nov 01

Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA

Aug 21

The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically

Aug 15

Cara Therapeutics: 200% Upside Possible With FDA Approval

Aug 11

Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive

Jul 19

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CARA şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CARA şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Cara Therapeutics Piyasaya Karşı Temettü Getirisi

CARA temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CARA)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Pharmaceuticals)	2.2%
Analist tahmini (CARA) (3 yıla kadar)	0%

Önemli Temettü: CARA şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CARA şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CARA şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CARA herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Cara Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 70% to US$1.52

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc.'s (NASDAQ:CARA) Price Is Right But Growth Is Lacking After Shares Rocket 34%

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

We Think Cara Therapeutics, Inc.'s (NASDAQ:CARA) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Cara Therapeutics, Inc.'s (NASDAQ:CARA) Low P/S

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Price target decreased by 12% to US$4.90

Full year 2023 earnings: EPS and revenues miss analyst expectations

We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Cara Therapeutics, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program

Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis

The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%

Consensus revenue estimates decrease by 39%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts

New major risk - Share price stability

Consensus revenue estimates increase by 19%

Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?

Cara Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 7.6% to US$17.29

New minor risk - Financial position

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

Cara Therapeutics, Inc. Appoints Helen M. Boudreau to Board of Directors

New minor risk - Share price stability

Cara Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?

Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 53%

News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat

Price target decreased by 18% to US$19.38

Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics Announces Appointment of Lisa Von Moltke, M.D., to Its Board of Directors

Cara Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients

Key Executive recently sold US$111k worth of stock

Cara Therapeutics, Inc Appoints Ryan Maynard as Principal Financial Officer and Principal Accounting Officer

Cara Therapeutics hires new finance chief

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Cara Therapeutics: All Eyes On Korsuva Launch Metrics

Kapruvia® Gets Approval in Switzerland with Additional Regulatory Decisions

Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Cara Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Cara Therapeutics, Inc. Announces Positive Topline Results from Komfort Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Calls A Much Safer Way To Buy Cara Therapeutics

We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate

Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Officer, Effective on or About June 15, 2022

Consensus revenue estimates increase by 19%

Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Vifor Fresenius Medical Care Renal Pharma (Vfmcrp) and Cara Therapeutics, Inc. Announces the European Commission Has Granted Marketing Authorization to Kapruvia

Cara Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Cara Therapeutics, Inc Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Taking A (Speculative) Position In Cara Therapeutics

Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 36%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announce CHMP Recommend Approval of Kapruvia for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients